Printer Friendly

ANGEION RECEIVES ADDITIONAL MARKET APPROVAL FROM JAPANESE GOVERNMENT

ANGEION RECEIVES ADDITIONAL MARKET APPROVAL FROM JAPANESE GOVERNMENT
    MINNEAPOLIS, Nov. 7 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) has received approval from the Government of Japan to begin marketing two additional lines of accessory devices in Japan. These product lines include the ANGETEAR(R), a dilator with tear-away sheath assembly, and the ANGEDAPT(R), a y-connector.
    In July, Angeion began shipping its ANGESTAT(TM), a line of vascular access devices, to Japan after receiving approval from the Japanese Government to market that device.  Angeion has an exclusive distribution agreement with Tokyo-based Sanix Company, Ltd., a Japanese distributor of medical devices.
    It is estimated that the total Japanese market for angiography and angioplasty accessories to be between $160 and $200 million.
    Angeion has applied to the Japanese Government for permission to market its ANGEFLATOR(R), an inflation device used in balloon angioplasty procedures.
    Minneapolis-based Angeion Corporation is a manufacturer of interventional accessory devices.  Sales from Angeion's core business, Angeion Medical Products, reached $6.5 million in fiscal 1991. Angeion's subsidiaries, AngeLase, Inc. and AngeMed, Inc., are developing several products for treating arrhythmias.  Angeion is traded on NASDAQ under the symbol ANGN and on the Boston Stock Exchange under the symbol ANI.
    -0-                          11/7/91
    /CONTACT: Brenda Roth of Angeion Corporation, 612-559-3370/
    (ANGN ANI) CO:  Angeion Corporation ST:  Minnesota IN:  MTC SU: AL- -- MN004 -- 2139 11/07/91 10:38 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 7, 1991
Words:228
Previous Article:NEW ENGLAND ELECTRIC SYSTEM COMPANIES BREAK NEW GROUND FOR CLEAN AIR
Next Article:SOUTHWEST AIRLINES REPORTS OCTOBER TRAFFIC
Topics:


Related Articles
ANGEION REPORTS FIRST QUARTER SALES UP 13 PERCENT
ANGEION RECEIVES APPROVAL TO MARKET ICD IN EUROPE
Angeion Receives Approval to Expand U.S. Clinicals of Sentinel ICD
Angeion Begins FDA Approved Clinicals of Sentinel 2010 ICD System
Angeion Reports Sentinel Sales up 232 Percent for Fiscal Year
Angeion Receives Pre-Market Approval from FDA for Sentinel ICDs; Compact, Feature Intensive ICDs to be Marketed to $960 Million U.S. Industry
Angeion Announces Three News Items: $5 Million Equity Investment; U.S. Clinical Studies of AngeFix Lead System; and European CE Mark to Market...
Angeion Reports 33 Percent Growth in ICD Sales in Third Quarter.
Angeion Files FDA Submission of its Lyra(TM) 2020 Series of ICDs.
Angeion Secures Financing, Reorganizes to Reduce Expenses and Improve Competitive Positioning.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters